Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medi-Cal Expansion May Be Next Case For NACDS; Suit Filed Against Florida

Executive Summary

NACDS expects a response by the end of April to its request that California submit a Medicaid state plan amendment for its pharmacy-level prescription drug discount program.

You may also be interested in...



Florida Rx Discount Program For Elderly To Receive HCFA Review

Florida will file a Medicaid state plan amendment for its program that offers Medicaid prescription drug prices to Medicare beneficiaries.

Florida Rx Discount Program For Elderly To Receive HCFA Review

Florida will file a Medicaid state plan amendment for its program that offers Medicaid prescription drug prices to Medicare beneficiaries.

Maine Prior Authorization May Be Rechallenged By PhRMA If Harm Is Shown

Maine's Rx rebate program can be challenged if the prior authorization aspect is harming patients, a federal appeals court said in overturning an injunction against initiation of the discount plan.

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel